Commitments And Contingencies (Narrative) (Details) $ in Thousands	1 Months Ended													3 Months Ended	9 Months Ended
	Oct. 31, 2018	Sep. 30, 2018 USD ($) distributor	Aug. 31, 2018 d product	Jun. 30, 2018 product theory	May 31, 2018	Apr. 30, 2018 case	Mar. 31, 2018 d defendant	Feb. 28, 2018 defendant claim	Jan. 31, 2018 d product employee	Oct. 31, 2017 patent product case defendant	Aug. 31, 2017 tranche product defendant	Dec. 31, 2016 state_attorney_general	Sep. 30, 2013 company	Sep. 30, 2018 USD ($)	Sep. 30, 2018 USD ($) case	Nov. 01, 2018 case claim	Dec. 31, 2017 USD ($)	Jul. 31, 2017 state	Mar. 31, 2017 state
Loss Contingencies [Line Items]
Reserve for loss contingencies		$ 1,002,100												$ 1,002,100	$ 1,002,100
Increase in legal reserves														200,000
Current portion of legal settlement accrual		966,633												966,633	966,633		$ 1,087,793
Vaginal Mesh Cases
Loss Contingencies [Line Items]
Current portion of legal settlement accrual		820,200												820,200	820,200
Payments to plaintiffs and qualified settlement funds															3,100,000
Settlement funds		283,752												283,752	283,752		$ 313,814
Testosterone Cases | Subsequent Event
Loss Contingencies [Line Items]
Pending claims, number | claim																1,205
Unapproved Drug Litigation
Loss Contingencies [Line Items]
Number of additional defendants | company													50
Number of claims consolidated | claim								5
Opioid-Related Matters
Loss Contingencies [Line Items]
Number of claims set for trial | case						3
Opioid-Related Matters | Subsequent Event
Loss Contingencies [Line Items]
Pending claims, number | case																1,505
Number of cases filed by states | case																11
Number of cases filed by hospitals, health systems, unions, welfare funds or other third-party | case																112
Number of cases alleging personal injury and/or wrongful death | case																48
Pricing Matters Cases
Loss Contingencies [Line Items]
Number of claims consolidated | case										2
Number of cases filed by states | state																		4	40
Number of products involved in claims | product				18						15
Number of state attorney generals | state_attorney_general												20
Number of defendants | defendant										14
Lidoderm cases
Loss Contingencies [Line Items]
Reserve for loss contingencies		100,000												100,000	100,000
AndroGel 1.62%
Loss Contingencies [Line Items]
Number of causation theories rejected | theory				2
Number of causation theories | theory				3
Bier v. Endo International plc, et al. | Current and Former Directors and Officers
Loss Contingencies [Line Items]
Number of additional defendants | defendant											4
Number of defendants | defendant								20
AMS | Vaginal Mesh Cases
Loss Contingencies [Line Items]
Product liability accrual, period expense		$ 845,600												$ 845,600	$ 845,600
Loss contingency, claims settled, number | case															71,000
Par Pharmaceutical, Inc. | Pricing Matters Cases
Loss Contingencies [Line Items]
Number of products involved in claims | product									30	13	1
Number of tranches for claims | tranche											3
Number of products allegedly manufactured by PPI | product									7
Par Pharmaceutical, Inc. | Pricing Matters Cases | First tranche
Loss Contingencies [Line Items]
Number of products involved in claims | product										6
Par Pharmaceutical, Inc. | VASOSTRICT Related Matters
Loss Contingencies [Line Items]
Number of additional defendants | employee									5
Number of patents allegedly infringed upon | patent										5
Number of defendants filing motion to dismiss the breach of contract claim | defendant							7
Number of defendants filing motion to dismiss for lack of personal injury jurisdiction | defendant							4
Number of defendants filing motion to dismiss breach of contract claim | defendant							1
Stay of litigation, number of days | d									60
Loss Contingency, Extension of Temporary Stay, Number of Days | d			180				180
Lawsuit filing period					45 days
Stay of approval period, hatch-waxman act					30 months
Par Pharmaceutical, Inc. | VASOSTRICT Related Matters | Subsequent Event
Loss Contingencies [Line Items]
Lawsuit filing period	45 days
Stay of approval period, hatch-waxman act	30 months
Endo Pharmaceuticals Inc. and Par Pharmaceuticals Inc. | Pricing Matters Cases
Loss Contingencies [Line Items]
Number of products involved in claims | product			16
Loss Contingency, Number of Distributors | distributor		1